Hope on the Horizon for TNBC
Expert Perspectives
Expert Perspectives

Hope on the Horizon for TNBC

Not a member of My prIME? Join now for instant access.

View posters, expert perspectives, and downloadable slides from our symposium at the 2017 Breast Cancer Annual Meeting in San Antonio Experts discuss current treatment approaches, biology, and novel treatment strategies for triple-negative breast cancer (TNBC), including antibody-drug conjugates, targeted therapies, PARP inhibitors, and immunotherapy.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credit™

Release Date

Release Date

Dec 21, 2017

Expiration Date

Dec 21, 2018

  • Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
    University of Milan
    Milan, Italy
  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Jorge Reis-Filho, MD, PhDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Andrew Tutt, MD, PhDInstitute of Cancer Research
    London, United Kingdom

Current treatment approaches: How I manage my patients
Harold J. Burstein, MD, PhD

Getting to grips with the biology of TNBC
Jorge Reis-Filho, MD, PhD

Aim at the heart: The opportunities provided by antibody-drug conjugates and targeted therapies in TNBC
Joyce O’Shaughnessy, MD

PARP inhibition in TNBC: Who, how, and when?
Andrew Tutt, MD, PhD

Immunotherapy for TNBC: Hope or hype?
Giuseppe Curigliano, MD, PhD

Posters relating to this activity:

Chemotherapy:

 Targeted Strategies:

 Immunotherapy:

 PARP Inhibitors:

 Combination Strategies:

This educational activity is specifically designed for medical oncologists and other healthcare professionals who treat and manage patients with breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess current and emerging clinical trial information concerning the use of investigational therapeutic approaches to care for patients with TNBC
  • Select the most appropriate treatment based upon patient and disease characteristics

This educational activity is supported by grants from AstraZeneca; Merck and Co, Inc.; and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Hope on the Horizon for TNBC - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Burstein has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Curigliano discloses that he has received consulting fees from Pfizer and Samsung. He also discloses that he has received honoraria from Pfizer and Roche, and that he is a member on an advisory committee or review panel for Lilly and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Shaughnessy discloses that she has received consulting fees from AstraZeneca, Celgene, Lilly, Novartis, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Reis-Filho has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tutt discloses that he has received consulting fees from AstraZeneca, Merck Serono, and Vertex.  He has also disclosed independent contractor work for AstraZeneca, and has served on an advisory committee or review panel for AstraZeneca and Merck Serono. He has received royalties from the ICR Rewards to Inventor’s Scheme. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) –performed contracted research for or received research support from Amgen and Bayer
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.